Prenetics: A Consumer Health Pivot Reaches Inflection

IM8 subscription engine drives 333% revenue growth, guidance raised, and Bitcoin sold to fund growth.

PRE · Earnings Call · 2026-05-14

The Reinvention Takes Hold

Danny Yeung opened the Q1 2026 call with a blunt capsule of what has changed: “The Prenetics that went public in 2022 was a diagnostics and genome testing business built around laboratory testing. A very different revenue model, a different growth profile. The Prenetics you see today is something entirely different.” That transformation is now visible in the numbers. On a continuing operational basis, total revenue for Q1 was $36 million, up 333% year-over-year, with IM8 contributing $33.8 million — nearly 6x the prior-year quarter. “Today, we are shipping to 43 countries, delivering approximately 150,000 servings every single day, and we are on tracking to reach roughly $186 million in annualized recurring revenue based on IM8's monthly revenue in May.” — Danny Yeung, Chief Executive Officer and Co-founder · 2026-05-14 The company is demonstrating that a once-fledgling subscription brand can scale globally, and the market is taking note.

The Quarterly Subscription Engine

The single most important operational change has been the rollout of quarterly subscription plans. After testing in the U.S. at the end of 2025, the company extended the offering internationally in Q1. The impact on unit economics is dramatic: new customer average order value jumped from $157 in Q4 2025 to $240 in Q1 2026 — a 53% sequential increase. This shift was a deliberate strategy, as Yeung had explained on the prior call: “So we actually started quarterly subscriptions in the U.S. first in December... it provides benefits for both sides.” The math is now showing up in cohort behavior. Management highlighted that the January 2026 quarterly cohort generated $587 in cumulative revenue per customer in just four months, versus $549 over twelve months for the January 2025 monthly cohort. As Yeung noted, “4 orders today equals 12 orders a year ago.” This compression in payback and improvement in cash flow is what allows the company to reinvest aggressively in marketing while maintaining strong retention. The subscription rate holds at 79% for new customers, and the company points to repeat revenue of 81% across mature cohorts — a metric that Yeung says puts IM8 “in a very different league on retention.”

That puts our net repeat revenue well ahead of every public DTC pair that discloses a comparable metric. Bell Ring at 52%, FIGS at 50%, Alidi at 45%. We are operating in a very different league on retention.
Danny Yeung, Chief Executive Officer and Co-founder · 2026-05-14

The success of the quarterly model is also reflected in the guidance. Management raised full-year 2026 IM8 revenue guidance to $190–$210 million, up from $180–$200 million, citing continued momentum in April and May (April IM8 monthly revenue was $14 million, up 18.6% month-over-month). For Q2, they expect total revenue of $46–$48 million, with IM8 contributing $44–$46 million — a ~33% sequential increase.

Product Roadmap and Capital Allocation

Ahead of Q4, the company announced three new product launches: hydration, Creatine, and kids’ gummies. These are not speculative side bets; they target large, fast-growing categories (hydration ~$37B, creatine ~$1.3B growing 26% y/y, kids’ supplements ~$3.6B) and each plays to the company’s existing strengths in premium, science-backed formulation and athlete credibility. The launches are largely incremental to the guidance, representing “pure upside.” While the company had previously mentioned two new SKUs in general terms — “Now due to competitive reasons, I think we don't want to release too soon what these 2 SKUs are” — the specificity of these categories and their attachment to the existing subscriber base underscore a deeper product-market fit strategy. Product market fit at scale is the phrase Yeung uses, and the cohort economics support that claim. On the capital front, the company sold its entire 510 Bitcoin position for $41.3 million, and the board adopted a policy to not purchase digital assets going forward. This is a clear pivot toward funding growth with certainty. Proceeds are earmarked for share repurchases (the company has already bought back ~$19 million of a $40 million authorization, and management personally added $2.75 million), accelerated DTC marketing, and the product pipeline. The message is that the consumer health business, not speculatively held crypto, is the best use of shareholder capital.

What It Means for Investors

The key takeaway is that Prenetics has transformed from a diagnostics company into a high-growth consumer health subscription business. The cohort data, the AOV uplift, and the retention rates are all pointing to a brand that has found its legs. The risk is execution: the company is scaling against a competitive landscape, and marketing spend (Q1 total of $22 million) is still high relative to revenue, but the payback math is improving. The new CFO, Brian Rosen, brings deep DTC experience, and his statement that “never seen LTV numbers like this” reinforces the internal conviction. In a market where many consumer brands are struggling to show unit economics, IM8 is demonstrating that a high-quality, equity-aligned athlete endorser roster combined with an AI-driven marketing engine can generate outsized growth. The company’s own trajectory — from a $60 million business last year to a potential $200 million this year — is a clear signal that the transformed Prenetics is being rewarded by the market. With 43 countries, 82,000 active subscribers, and a pipeline of new products, the runway remains substantial. Whether the company can sustain this pace into 2027 and beyond will depend on execution, but the evidence so far is compelling.